Arrhythmias & electrophysiology
Early Outcomes With a Next-Generation Dual-Seal Left Atrial Appendage Occluder: Results From the VERITAS Study
Authors' conclusion
The VERITAS study demonstrates high implant success of the next-generation dual-seal LAAO device, and a favorable short-term safety and sealing profile. (Abbott Medical-VERITAS Study; NCT06707688).
Study context
- Population
- Atrial fibrillation patients with CHA2DS2-VASc ≥2 for men and ≥3 for women undergoing left atrial appendage occlusion (LAAO) with the next-generation dual-sealing deviceenrolled and underwent an implant attempt
- Participants
- 400 patients
- Outcome
- Primary effectiveness endpoint: LAAO (leak ≤5 mm) by transesophageal echocardiography, independent core laboratory
- Follow-up
- 45 days
Methodological details34 global sites, independent core laboratory assessment of transesophageal echocardiography
- 34 global sites
- Independent core laboratory assessment of transesophageal echocardiography
Main finding
As reported in the abstract
Amulet 360
100%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| LAAO implant success | Amulet 360 99.8% |
| Complete LAAO (0 mm leak) · 45 days | Amulet 360 93.9% |
Baseline characteristics
- Age
- 73.8 ± 7.4 years
- Men
- 62%
- CHA2DS2-VASc
- 4.1 ± 1.4
- HAS-BLED
- 3.1 ± 1.0
Safety
| Outcome | Values |
|---|---|
| Primary safety endpoint: key adverse events through 7 days postprocedure or hospital discharge, whichever was laterPrimary safety endpoint | Amulet 360 0.0% |
| Pericardial effusion requiring percutaneous draining | Amulet 360 0.5% |
| Device-related thrombus | Amulet 360 2.4% |
Original publication
Early Outcomes With a Next-Generation Dual-Seal Left Atrial Appendage Occluder: Results From the VERITAS Study. JACC Clin Electrophysiol. Published 6 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →